

Diabetic retinopathy

Review Questions

NICE guideline TBC

Review Questions

July 2023

Disclaimer

The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, professionals are expected to take this guideline fully into account, alongside the individual needs, preferences and values of their patients or service users. The recommendations in this guideline are not mandatory and the guideline does not override the responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and, where appropriate, their carer or guardian.

Local commissioners and providers have a responsibility to enable the guideline to be applied when individual health professionals and their patients or service users wish to use it. They should do so in the context of local and national priorities for funding and developing services, and in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Nothing in this guideline should be interpreted in a way that would be inconsistent with compliance with those duties.

NICE guidelines cover health and care in England. Decisions on how they apply in other UK countries are made by ministers in the [Welsh Government](#), [Scottish Government](#), and [Northern Ireland Executive](#). All NICE guidance is subject to regular review and may be updated or withdrawn.

Copyright

© NICE 2023. All rights reserved. Subject to [Notice of rights](#).

Contents

1	Review Questions.....	5
---	-----------------------	---

1 Review Questions

RQ 1 What are the prognostic factors for the progression of non-proliferative diabetic retinopathy in people with diabetic retinopathy to:

- proliferative diabetic retinopathy
- diabetic macular oedema
- diabetic macular ischaemia?

RQ 2 What is the effectiveness of different thresholds or criteria for starting treatment for:

- non-proliferative diabetic retinopathy,
- proliferative diabetic retinopathy
- diabetic macular oedema?

RQ 3 What is the effect of intensive treatments to rapidly lower blood glucose levels on progression of diabetic retinopathy and diabetic macular oedema?

RQ 4 What is the effectiveness of lipid modification therapies and antihypertensive medicines to reduce the risk of progression of non-proliferative diabetic retinopathy?

RQ 5 What is the effectiveness and acceptability of anti-vascular endothelial growth factor agents and laser photocoagulation (alone or in combination) for the treatment of non-proliferative and proliferative diabetic retinopathy without macular oedema?

RQ 6 What is the effectiveness of vitrectomy surgery alone, or in combination with other treatments for treating proliferative diabetic retinopathy and macular oedema?

RQ 7 What is the effectiveness and acceptability of intravitreal steroids, laser photocoagulation and anti-vascular endothelial growth factor agents for treating diabetic macular oedema?

RQ 8 What are the clinical features or factors that suggest treatment should be switched or stopped for people diagnosed with proliferative diabetic retinopathy or diabetic macular oedema?

RQ 9 In people who are about to undergo or who have undergone cataract surgery, what is the effectiveness of treatments (before, during or after surgery) for managing:

- non-proliferative diabetic retinopathy
- proliferative diabetic retinopathy
- diabetic macular oedema?

RQ 10 What is the effectiveness of different monitoring frequencies for people with non-proliferative retinopathy whose care is managed under the hospital eye services but who are not having treatment?

RQ 11 What is the effectiveness of different monitoring frequencies for people with proliferative diabetic retinopathy or diabetic macular oedema that are receiving treatment or have had previous treatment?

RQ 12 What is the diagnostic test accuracy of ultra-wide field imaging and optical coherence tomography for monitoring?

- people diagnosed with non-proliferative diabetic retinopathy, whose care is managed under the hospital eye services, but who are not having treatment?
- people diagnosed with proliferative diabetic retinopathy or diabetic macular, who are having treatment or have had previous treatment?